Close
Digital Health & Ai Innovation summit 2026
Medical Taiwan 2026

Why Self-Management Is Crucial to Critical Care – How Telehealth Helps Achieve it

Today, self-management has become increasingly important in healthcare, more so in critical care, commonly referred to as chronic disease management. 

Now, since chronic illnesses represent a plight not just for the millions of affected patients, but also for the care providers and the health infrastructure as a whole, the significance of finding a powerful means of intervention has become a priority in the industry.

In one recent study published in the American Journal of Public Health, the author writes:

For both clinical and economic reasons, the increasing number of persons living with chronic conditions represents a public health issue of growing importance, creating a situation in which self-management will continue to grow as a crucial approach to managing these conditions.

Virtual consults, commonly referred to as ‘telehealth’ can be leveraged as an effective solution on this front, especially when it comes to encouraging patients to follow a proactive care approach. 

In this piece, we will be looking at 

-why self management is crucial to critical care, and 

– how telehealth can help achieve this.

Why Self-Management is Crucial to Critical Care?

Since chronic conditions are usually long in their duration but comparatively slow in progression, self-management analysis translated into practice can offer those living with such diseases a means to conserve or even better their capacity to remain healthy and conscious over the course of their lives.

Some of the ways healthcare providers can help patients tackle chronic illnesses by inculcating within them self management best practices include:

  • Educating patients about the importance of self-responsibility to their happiness and wellbeing,
  • Formulating a plan to achieve personal health goals, and precisely defining them,
  • Inspiring patients to make positive lifestyle changes, and
  • Identifying support strategies for dealing with depression, fatigue, pain, or stress.

One might think that much of this sounds like a basic approach to proactive care. However, various studies have also depicted an increasing need to focus on self-management in patients suffering with chronic diseases.

Because the persistent and profound harmful effects linked with chronic illnesses can lead to an elevated “symptom burden” — or the negative psychological, physiologic, and emotional consequences — such patients often feel too overwhelmed to participate in positive self-management behaviors without intervention.

For instance, chronic care patients with congestive heart failure (CHF), diabetes, and chronic obstructive pulmonary disease (COPD) may simply “tune out” some of the instructions provided by caregivers because of this symptom burden, which can worsen it further.

So then, what exactly can healthcare providers do to keep this from happening?

The answer is simple: leverage telehealth!

1) Telehealth Increases Access to Specialty Care

According to one recent study conducted by the Pew Research Center, approximately 46 million Americans reside in the nation’s rural regions at present. This points out that a considerable number of patients across the United States lack access to proper healthcare, and that they have to travel long distances just to be able to see a primary care provider at times.

In the case of patients with chronic conditions, they greatly rely on specialist care when trying to control their symptoms. Speciality care providers can be difficult to access in certain remote regions of the country. This makes it more arduous for chronically ill patients to consult doctors on a regular basis.

Telehealth solutions are rapidly helping healthcare organizations to provide people in rural regions with access to efficient and cost-effective solutions for managing chronic diseases from the comfort of their own homes.

For example, remote patient monitoring (RPM) works on the concept of leveraging virtual consultations in combination with the internet of medical things (IOMT) and medical devices. By using connected technology to transmit patient data to their care providers, telehealth helps patients gain access to specialist care, irrespective of their geographical location. 

2) Telehealth Helps Reduce Hospital Readmissions and Overall Care Costs

Patients with chronic diseases account for a little over 81% of all hospital admissions in America. This being a significant number, placing better chronic disease management strategies in place would also mean there will be comparatively fewer hospital readmissions.

How is this possible?

When physicians and specialists monitor a patient’s condition remotely through telehealth, they can help the patient better follow their symptoms and alter the treatment path when the need arises. This considerably mitigates the risk of them having to be readmitted to the hospital. 

Telehealth can also, by virtue of its ability to maintain contact isolation, be optimally used to help ameliorate outcomes for patients who may be immuno-compromised. Its adoption is a win-win situation for both healthcare providers and their patients.

While care providers can leverage telemedicine to ensure patients are following recommended lifestyle changes, answer questions about their medications, and triage new symptoms swiftly to keep hospital readmission rates as low as possible; patients can leverage this technology to better manage their symptoms and cut down on their cost of care.

3) Telehealth can be Used to Place Patients’ Health in their Own Hands

More often than not, chronic diseases demand lifestyle changes.

When left on their own, a few chronically ill patients may find it difficult to follow through on the treatment plans suggested by their physicians, which means there are increased chances of their condition deteriorating further.

Getting a telemedicine app developed for your practice or hospital that keeps a live record of an individual’s exercise, diet and medication regimen, and embeds features to track vital signs would be an excellent option to keep patients invested in their own health. It will also improve patient compliance rates across the facility. 

Customized push notifications sent through such an app can prompt patients about eating healthy, adhering to their medication schedule, or even furnish suggestions as well as tips for them to stay active. This pushes them toward a better lifestyle. 

With a current RPM report of patient vital signs and IOMT diagnostics available to them during virtual consultations, healthcare providers receive a more comprehensive view of how treatment is progressing and what changes should be made with the treatment regimen to improve outcomes. 

One best practice here would be to store all patient data on the facility’s cloud server. This boosts its interoperability across the healthcare organization and increases its accessibility so that the concerned physician can check it at any given point in time through something as convenient as their cell phone.

All in all, telehealth adoption can greatly benefit chronically ill patients trying to self manage their condition.

As forward-looking healthcare leaders, we constantly need to be on the lookout for ways we can make the transition to patient-centric, and value based care more seamless. Telehealth is definitely one state-of-the-art tech innovation that can help us do just that.

Important Information About The Healthcare Industry

Important Information About The Healthcare Industry

Every country has a healthcare industry in place, although not many people fully understand what this means. The professionals within this sector have great responsibility when it comes to their patients, but patients should also take responsibility for their own health.

This article will provide you with important information about the healthcare industry so that you are more knowledgeable in this area.

What is The Purpose of the Healthcare Industry

Looking after the health of individuals of every country is the responsibility of the government. This is why healthcare establishments were created. These places aim to enhance patients’ health by offering a range of treatments and access to healthcare professionals of different areas of expertise. Patients expect high-quality levels of the service provided and that their needs are met. This can sometimes prove to challenge as there is a high demand for healthcare services across the globe, which is hard to meet. Patients should expect to be treated fairly and equally and to have their needs taken into consideration, although this is not always the case.

Public VS Private

In the majority of countries, patients will have the opportunity to choose between public and private health sectors. The key differences between the two are that the public sector, as the name suggests, is accessible to the general public. Professionals within the public establishments are often more overworked as more people attend the services here. People from low socioeconomic backgrounds usually have no choice but to use the public service as it is considerably more affordable and funded by the government. The private sector, on the other hand, is more expensive, but the quality of care provided may be higher as a result. They may also provide certain treatments that are not available within the public health sector.

What is a Personalized Healthcare Approach

The healthcare industry is always changing to ensure that patients receive the care they need and deserve. A fairly new concept is the personalized healthcare approach, which not many people are familiar with. You may be familiar with the frustration of seeing your doctor very quickly, only to barely explain your symptoms before you leave their office with a prescription to treat your illness. This is because healthcare professionals in general practices use a generalized way of working. A personalized approach requires staff to focus on the patient and to tailor the treatment specifically to the patient’s needs, symptoms, and health background. This method of delivering healthcare is mainly provided within the private sector, as discussed previously.

Why The Need for Health Insurance

In the majority of countries, you will be required to pay for your medical expenses. Every time you see a doctor or get a prescription, you are expected to pay for this. This is why there are a number of insurance providers available, such as Medicare, for example. Even if you are a considerably healthy individual and you look after your health, you can never predict whether you will face a health issue. Having appropriate insurance in place will ensure that you can afford this. These plans generally require you to pay a set premium every month and should provide you with access to most healthcare practices, depending on the type of plan that you purchase. Make sure that you fully understand what this entails with Medicare Help AZ so that you can have your questions answered. This will help you find the best plan for your healthcare needs.

The Implementation of Technology Within Healthcare

The use of technology within the healthcare system is increasing, particularly in a recent couple of years as the world faced a global pandemic and most services were strictly provided remotely. This can be beneficial as there is the possibility of booking appointments online or even having remote appointments over the phone or video call. However, as you can imagine, this will not be the best option for every health condition or every patient.

What Can We Do As Individuals to Support The Healthcare Industry

We are constantly thinking about how the healthcare industry can improve to support us as patients, although many individuals neglect their own health and forget to take responsibility for their actions. Although no one has 100% control over their health, there are a few things that we can all do to ensure that we live a healthy life. Evidently, starting by eating a healthy and balanced diet and taking part in regular physical activity. These may seem like simple steps but they can make a massive difference in a patient’s overall health and reduce the likelihood of many health issues, including heart disease and overweight issues.

Although the majority of us use healthcare services at some point in life, not everyone knows much about it. This page should provide you with important information about the healthcare industry that you may not already be aware of.

GE Healthcare and Minerva Imaging sign strategic partnership to accelerate precision medicine and targeted radionuclide therapy

GE Healthcare and Minerva Imaging sign strategic partnership to accelerate precision medicine and targeted radionuclide therapy

GE Healthcare and Minerva Imaging have announced a strategic partnership with the aim to bring targeted radionuclide therapies (Theranostics) faster to the market. Radionuclide therapy is a form of precision medicine where a radioactive substance is administered through the bloodstream to specifically target cancer cells and irradiate them. This helps reduce potential side effects compared to traditional cancer therapies. Recent years have seen strong growth in targeted radionuclide therapies.

Adding to its 2,000 m2 R&D site, Minerva Imaging will open a new facility in 2022 and expand its R&D footprint by 50%. The Denmark-based company expects to employ over 100 people at the new facility by the end of 2022. The expansion will give the company the extra capacity it needs to meet growing demand in the radionuclide therapy sector.

The partnership with GE Healthcare is designed to facilitate the success of Minerva Imaging’s growth plans by establishing capabilities for in-house production of isotopes and CDMO services for radiopharmaceuticals. Minerva Imaging will be using cutting-edge technology from GE Healthcare to optimize new radiopharmaceuticals, including a cyclotron – a type of particle accelerator used to produce isotopes.

GE Healthcare will support Minerva Imaging to set up Good Manufacturing Practice (GMP) production in the new facility. This will help ensure high quality products for Minerva Imaging’s clients which, in turn, will support the best possible outcomes for patients. GE Healthcare and Minerva Imaging will work in partnership to innovate and optimize manufacturing protocols for new radioisotopes by sharing knowledge and expertise related to technological innovation.

Simon McGuire, Northern Europe Regional General Manager at GE Healthcare, said: “Minerva Imaging could with this expansion become an important player in clinical development of life-saving medicines. GE Healthcare has, for many years, through our Imaging and Pharmaceutical Diagnostics businesses, been building technology and radiopharmaceuticals that help enable precision health. Now, together with Minerva Imaging, we have the opportunity to further accelerate efforts in this space.”

Carsten Nielsen, CEO and co-founder of Minerva Imaging, said: “Partnering with a global leader like GE Healthcare is a major milestone for Minerva Imaging. Together, we have the capacity to work on more innovative therapies, accelerate their route to market and treat more patients with the targeted therapy. There are only winners in a collaboration like this.”

GE Healthcare offers medical practitioners the tools and support they need to improve patient-centered care and advance the practice of precision medicine. Through this partnership and a variety of other partnerships and solutions, GE Healthcare aims to further reinforce its role as a core partner in improving cancer care.

About GE Healthcare:

GE Healthcare is the $17 billion* healthcare business of GE (NYSE: GE). As a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 47,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world. 

About Minerva Imaging ApS:

Minerva Imaging is a scientifically driven CRO founded in 2011. The company focuses on the use of advanced models and molecular imaging for translational research and drug development. Minerva Imaging engages with its clients to understand their scientific questions and discuss how its methods and capabilities can provide answers. The company’s competences build on more than two decades of research within oncology, cardiovascular disease and molecular imaging performed at the University of Copenhagen and Rigshospitalet, the National University Hospital of Denmark.

SCL Health Partners With Acadia Healthcare To Grow Behavioral Health Services

SCL Health Partners With Acadia Healthcare To Grow Behavioral Health Services

SCL Health has formed a joint venture partnership with Acadia Healthcare, a national behavioral healthcare provider, to expand its commitment to providing behavioral health services. The joint venture will allow SCL Health to help meet the growing demand for behavioral health treatment for members of the community of all ages.

Acadia is committed to patient- and family-centered care, clinical outcomes, and it has a proven track record of collaborating with similar health systems across the country. “We believe that access to high-quality mental health care is important to our community, and we are partnering with Acadia to expand that access significantly in the coming years,” said Lydia Jumonville, President, and CEO of SCL Health.

During the first phase of the partnership, SCL Health West Pines will continue to deliver high-quality behavioral health services as it has for three decades at its current location. A transitional management agreement allows both organizations to work closely together to ensure a smooth transition and maintain a strong philosophy of care.

“Acadia is proud to be partnering with a premier health system like SCL Health,” said Debbie Osteen, Chief Executive Officer of Acadia Healthcare. “As part of the ongoing phases of this partnership, we look forward to creating a new patient-centered facility that will provide healing for those in need.”

The joint venture between SCL Health and Acadia Healthcare plans to build a new and expanded behavioral health hospital in the same region with an anticipated opening date in the middle of 2023. When the new facility is operational, the next phase of the partnership will begin.

“This partnership solidifies our commitment to meeting the growing demand for safe, accessible, compassionate, affordable, and high-quality behavioral health services in the communities we serve,” said Grant Wicklund, Lutheran Medical Center President.

About SCL Health

SCL Health is a faith-based, nonprofit healthcare organization dedicated to improving the health of the people and communities we serve. Founded by the Sisters of Charity of Leavenworth in 1864, our health network provides comprehensive, coordinated care through eight hospitals, more than 180 physician clinics, home health, hospice, mental health, and safety-net services in Colorado and the Montana Wyoming region.

About Acadia Healthcare

Acadia is a leading provider of behavioral healthcare services across the United States. As of June 30, 2021, Acadia operates 229 behavioral healthcare facilities with approximately 10,100 beds in 40 states and Puerto Rico. With more than 20,000 employees serving about 70,000 patients daily, Acadia is the largest stand-alone behavioral health company in the U.S. Acadia provides behavioral healthcare services to its patients in various settings, including inpatient psychiatric hospitals and specialty treatment facilities, residential treatment centers, and outpatient clinics.

 

Medical schemes industry body welcomes announcement of lower cost for Covid-19 PCR tests

COVID-19 qPCR Test Kits

The Health Funders Association (HFA) welcomes the announcement by the Competition Commissioner, Mr Tembinkosi Bonakele, that the price of the Polymerase Chain Reaction (‘PCR’) Covid-19 tests has been reduced from R850 (including VAT) and any other charged amount to R500 (including VAT) per test with immediate effect.

HFA has expressed its concerns relating to the high price for Covid-19 PCR tests since November 2020 and, on behalf of its members, attempted on numerous occasions to engage with the National Pathology Group (NPG; the representative association of the pathology laboratories), in an effort to secure a downward revision of the prices under the current block exemptions, which allow medical schemes to address the PCR pricing directly with the pathologists.

Despite these efforts, regulatory intervention was required to secure a price reduction.

In terms of Prescribed Minimum Benefit (‘PMB’) regulations, medical schemes are compelled to pay in full for Covid-19 PCR tests when a doctor has referred them, subject to specific criteria being met by the patient, regardless of the outcome of the test. The PMBs were put in place to ensure that all medical scheme members can access health services relating to Covid-19, irrespective of the benefit option they are on.

The issue of Covid-19 test pricing is an important case study, demonstrating the extent to which the regulatory requirement for medical schemes to cover PMBs at cost significantly impairs their ability to negotiate lower pricing for the sake of affordable access for all.

HFA is grateful to the Council for Medical Schemes (‘CMS’) for lodging the formal complaint with the Competition Commission that the excessive price for Covid-19 PCR tests is in contravention of Section 8(1)(a) of the Competition Act read with paragraph 4 of the Regulations.

“We are grateful to the Competition Commissioner for stepping in. We believe that the Covid-19 pandemic calls for the entire health industry to work together in minimising both the human and financial impact of this unprecedented time”, says Ms Lerato Mosiah, CEO of HFA.

She went on to say, “we hope that this will lead to greater scrutiny of the pricing of services that medical schemes are obligated to fund at cost under the prescribed minimum benefits.”

While this outcome is positive, further discussion and collaboration with all relevant stakeholders is required to ensure that all related services and products are appropriately costed, and affordable in order to increase access by all citizens.

The HFA also believes that it is important that the Health Market Inquiry recommendations are implemented to ensure that there is adequate tariff determination mechanisms in place in future. To this end, the HFA supports the CMS’ continued efforts in this regard, in collaboration with and under the oversight of the Competition Commission.

Post Concussion Syndrome: Common Symptoms

Post Concussion Syndrome: Common Symptoms

Post-concussion syndrome (PCS) refers to the persistent symptoms following a concussion sustained by a mild traumatic brain injury (TBI). This can occur for a number of reasons such as a stroke, car accident or a blow to the head. An indirect impact to the head can also lead to a concussion as in the case of whiplash.

The symptoms of PCS usually linger for weeks or months after the head injury and can include headaches, fatigue, memory loss, dizziness as well as behavioral issues such as anxiety and depression.

This article will outline some of the signs that will help you determine whether you or someone you know may be suffering from PCS.

PCS Symptoms

PCS symptoms may differ from those you experience from your injury. For instance, it may be that your dizziness goes away, yet you find it increasingly difficult to concentrate.  Although PCS symptoms will vary from person to person, some of the common physical, emotional and cognitive symptoms that are diagnosed are listed below:

Headaches: Post-concussion headaches can feel quite different from normal headaches. Cervicogenic headaches are commonly reported after a trauma to the head. These headaches, often start at the back of the head, can create tension in the neck and are associated with pain on one side of the body.

Light sensitivity and Sight problems: Some people can experience problems with their vision following a concussion. According to Optometry and Vision Science, over 40% of people with a brain injury are sensitive to light. Other symptoms might include blurry vision,  difficulty in focusing and peripheral vision problems.

Sleep Problems: many people experience problems sleeping after being diagnosed with a concussion. The symptoms vary from hypersomnia, where the person is sleeping excessively, to insomnia. It is also possible for circadian rhythm shifts to occur in people who have sustained a brain injury.

Fatigue: A concussion from a mild TBI can cause fatigue due to changes in the brain. If you find that you are tired much of the time, wake up exhausted despite having slept well or have little energy to work for more than a couple of hours first thing in the morning then you may be experiencing fatigue as a result of PCS.

Memory loss: PCS can lead to issues with memory such as brain fog, short or long-term memory loss and difficulties focusing. Poor concentration may be the result of physical issues such as neck pain, migraines, and vision problems, as well as psychological reasons like anxiety and increased sensitivity to light and noise.

Brain Fog: A common symptom of PCS, brain fog can be characterized by slowness in thinking, delayed responses and difficulty learning and remembering new information. These symptoms are most common in the first few months after a concussion. Persistence in these symptoms is indicative of other underlying emotional issues such as depression.

Depression: Many patients report mood-related symptoms and changes to personality following a TBI. Depression is commonly experienced within the first twelve months following an injury to the head and can last several years.

These are some of the most common issues to look out for if you or someone you know has recently experienced a head injury.

How Heart Problems Can Affect Your Breathing

How Heart Problems Can Affect Your Breathing

Heart ailments are the leading cause of hospitalizations and mortality for people of all ages. They’re developed congenitally, and they can also be acquired, sudden attacks. Early diagnosis and prompt intervention are vital to prevent worsening conditions.

Studies show that cardiac problems aren’t limited to chest pain. When a person is struggling to breathe, you must know the other symptoms that may help to distinguish between a heart attack or a seizure. For example, agonal breathing or insufficient breathing may indicate cardiac arrest. A proper first-aid application is crucial in keeping them alive before responders arrive. You may visit https://avive.life/ to learn more about agonal breathing.

The heart and lungs work in pairs to deliver oxygen-rich blood to all body tissues. Defects and malfunction disrupt the systemic blood circulation, decreasing the body’s oxygen (O2) level, which results in breathing problems.

This article would discuss how heart problems can affect your breathing.

Anatomy And Physiology Background Of The Heart

The heart is mainly responsible for collecting deoxygenated blood and transporting oxygenated blood from the lungs to the body’s periphery. It’s a hollow muscular organ that lies in the mediastinum, and its size is about a human’s fist.

The heart function is composed of the pulmonary and systemic circuit:

  • Pulmonary Circuit

The role of the lungs is to filter deoxygenated or venous blood that comes from tissues throughout the body.

Deoxygenated blood returns to the heart via veins to the vena cavae and onto the heart’s right atrium. Following is its entrance down to the right ventricle via the tricuspid valve. It leaves the right ventricle via the pulmonary artery; deoxygenated blood will travel to the lungs for filtering and return as oxygenated blood to the heart’s left atrium via the pulmonary vein.

  • Systemic Circuit

This loop delivers oxygenated blood to the body’s tissues and cells. Lack of oxygenated blood will lead to inefficiency and malfunction of the body’s organs and systems. Oxygen-rich blood leaves the heart via the left ventricle to the aorta and from there enters the arteries and capillaries, where it supplies the body’s tissues and cells with oxygen.

The two physiologic functions of the heart are essential for the body’s balanced and sufficient O2 level saturation, and this element can be monitored through an oximeter. It determines the amount of oxygen that the organs and extremities are receiving.

Hypoxemia, or the decrease in O2 level of the body, is harmful to the organs such as the brain, heart, lungs, and kidney. When these structures are compromised, the body won’t function efficiently, resulting in life-threatening conditions.

These are the anatomic structures that connect the heart to the lungs:

  • Pulmonary Vein

This carries deoxygenated blood from the right ventricle to the lungs.

  • Pulmonary Valve

This prevents the backflow of deoxygenated blood from the lungs to the right ventricle.

  • Pulmonary Artery

This carries oxygenated blood from the lungs to the left atrium.

Breathing

The purpose of breathing is to deliver O2 and eliminate carbon dioxide (CO2)from cells throughout the body. Breathing is an act of ventilation and respiration in which an exchange of O2 and CO2 occurs. It’s an automatic regulatory process where the levels of CO2 are detected and constantly sent to the brain’s medulla.

The medulla is the body’s main respiratory center, and it signals the respiratory muscles to regulate ventilation, leading to healthy and efficient breathing.

Central chemoreceptors monitor CO2 levels; they’re located near the medulla while peripheral sensors are located in the carotid body and aortic arch. They respond to the increase and decrease of CO2.  As CO2 increases, the medulla signals for an increase in respiration.

Heart Problems That Affect Breathing

The following are the most common heart problems that can affect your breathing:

  1. Pulmonary Atresia

Pulmonary atresia is a congenital disability of the heart. There’s an absence of the pulmonary valve that controls blood flow from the heart to the lungs. There’s difficulty in blood to travel to the lungs and pick up oxygen for the body.

Babies have rapid or slow breathing, leading to cyanosis or the bluish-purple color of the skin due to lack of oxygen.

  1. Coronary Artery Disease

Coronary artery disease (CAD) happens when the blood vessels supplying your heart with oxygen, blood, and nutrients are damaged. It’s an umbrella term for the following:

  • Myocardial Infarction

This is also called a heart attack. When a blood clot or plaques block the heart’s blood flow, an area of the heart dies due to disrupted blood flow and decreased oxygen.

  • Acute Coronary Syndrome

This refers to the conditions where the heart muscle’s blood supply is suddenly blocked. This will lead to an insufficient supply of oxygenated blood to the body parts.

  • Atheroma

This occurs when fat, cholesterol, calcium, connective tissues, and inflammatory cells adhere to the arteries. It’ll compromise blood flow in the heart and body even if it’s only a partial blockage.

Patients experience shortness of breath (SOB), palpitations, and chest pain.

  1. Pulmonary Stenosis

Pulmonary stenosis occurs when the valve between the right ventricle and pulmonary artery is damaged. Pulmonary valve will become stiffened, narrowed valve opening, and reduced blood flow. There’s SOB, chest pain, tightness, and palpitation.

  1. Left Congestive Heart Failure (CHF)

Left CHF occurs when there’s an impaired gas exchange or pulmonary edema. This condition leads to decreased cardiac output or pulmonary congestion.

Here are the significant manifestations of left CHF that affects breathing:

  • Dyspnea

This is also known as an SOB due to vascular congestion, which reduces lung oxygenation.

  • Orthopnea

This is dyspnea in a lying position and is usually alleviated by head elevation. There’s pooling in the heart’s major blood vessel network, resulting in higher cardiac volume, increased left ventricular filling pressure, and pulmonary congestion.

  • Paroxysmal Nocturnal Dyspnea

This is the sudden waking up at night with severe SOB or cough. It’s due to lying flat at night, the medulla becoming less responsive at sleep, and decreasing adrenalin.

  • Pulmonary Edema

This is the fluid accumulation in the lungs, which leads to inefficient breathing.

  • Hacking Cough

This is a common symptom of left CHF. It produces frothy white, pink, or blood-tinge sputum.

  1. Rheumatic Heart Disease (RHD)

RHD is when one or more heart valves are damaged after healing from acute rheumatic fever (ARF). The heart becomes inflamed and remains stretched or scarred even when ARF resolves. There’s a blood backflow in the mitral, tricuspid, and pulmonary valves.

RHD results in inefficient blood flow in the heart and the body, thus compromising the blood O2 level. The symptoms are SOB, chest pain, and discomfort.

Risk Factors For Having Heart Problems

Here are some factors that could affect your heart’s condition:

  • Family history
  • Age
  • Sex
  • Sedentary lifestyle
  • Smoking
  • Imbalanced diet
  • Diabetes
  • Stress
  • Hypertension
  • Liver and kidney diseases
  • Maternal alcohol and nicotine abuse

Final Word

Heart problems have a domino effect: insufficient blood flow, a decrease in oxygen level saturation, receptors signal and alarm the medulla, and when the heart fails to respond, it leads to unproductive breathing.

Cardiac ailments are inevitable yet may be preventable. It can lead to life-threatening diseases when undiagnosed and undetected. It’s essential to distinguish heart problems and know basic life support to help save lives.

MedicaMetrix and Emerson Hospital Announce Partnership for establishing Urology Centers of Excellence Globally

Humana and REACH Kidney Care Sign Care Coordination Services Agreement

MedicaMetrix Inc announced a collaboration with Emerson Hospital’s Yeatts Urology Center (Concord, MA) to improve patient care by establishing international centers of excellence for urology.

The companies have agreed to explore establishing premier centers of excellence for urology. Using Emerson Hospital’s urologic care-delivery model as a template for emulation in parts of the United States, and internationally in India, Asia, the Middle East, Canada, Europe, Mexico, and South America, MedicaMetrix will build the infrastructure and foster clinical collaborations for expansion. The partnership highlights the importance of bringing targeted therapy for prostate and other cancers to international markets, including Europe and the Middle East.

Spearheading the model of advanced urological care is Dr. John Libertino of Emerson Hospital and his team. Under the leadership of Dr. John Libertino, the Yeatts Urology Center has developed a model for exceptional urological care delivery. The center brings advanced treatments to patients, from general urological care to highly specialized treatment, including complex surgery, targeted therapy, and cancer care.

Joining the team from the Yeatts Urology Center are members of MedicaMetrix’s executive team including Chairman Satish Vankayalapati, Chief Scientific & Medical Officer Dr. Peter Madras, and Head of Business Development and Strategy Vyda Bielkus. The collaboration’s guiding principles are improving patient care, developing purpose-driven research collaboration, and creating meaningful educational exchanges and training opportunities to improve patient outcomes and reduce patient risk.

“We are incredibly excited to be partnering with Dr. Libertino and his team at Emerson” said MedicaMetrix Chairman Satish Vankayalapati, “By partnering with such a high-level, world-class organization we believe we can improve patient care around the world.”

Additionally, the partnership will foster collaborations for MedicaMetrix’s cutting-edge medical devices, diagnostic tools, and advanced treatment options for urological disease management.

“Incredible advancements are being made in urology and prostate cancer treatment and disease management. Expanding our reach in this partnership is an important step in expanding global collaboration for bringing the best care to patients around the world,” said Dr. John Libertino.

QIAGEN and Denovo Biopharma Partner to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma

QIAGEN and Denovo Biopharma Partner to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma

QIAGEN and Denovo Biopharma LLC announced a collaboration to develop a blood-based companion diagnostic (CDx) test to identify patients expressing Denovo Genomic Marker 1 (DGM1TM) who are likely to respond to Denovo’s investigational cancer drug DB102TM for treatment of diffuse large B-cell lymphoma (DLBCL), one of the most common lymphoid cancers.

Under the agreement, QIAGEN will develop a diagnostic assay that can detect the Denovo Genomic Marker 1 (DGM1TM) in DLBCL patients, a biomarker discovered by Denovo that predicts the responsiveness to DB102. Also known as enzastaurin, Denovo’s drug is a first-in-class investigational small molecule inhibitor of PKC-beta, a protein whose presence has been compellingly linked to DLBCL cases.

“We are proud to be at the cutting edge of precision medicine, a quantum leap from traditional one-drug-fits all medicine,” said Jonathan Arnold, Vice President, Head of Oncology and Precision Diagnostics at QIAGEN. “Our molecular testing expertise will help Denovo to develop the use of the DGM1 marker with the DB102 drug for patients with DLBCL.”

QIAGEN will develop a real-time qualitative PCR companion diagnostic for the QIAGEN Rotor-Gene Q MDx instrument and apply for premarket approval (PMA) with the US-based Food and Drug Administration (FDA). The goal is to get the PMA for the test contemporaneously with Denovo receiving new drug application (NDA) approval for its DB102. The drug and the DGM1 marker are currently in a phase III trial, called ENGINE, on newly diagnosed, high-risk DLBCL patients.

“As our ENGINE trial nears completion, we are pleased to be working with QIAGEN on commercial development of our DB102 program to enable patients and physicians to potentially benefit from DB102 treatment,” said Xiao-Xiong Lu, Denovo’s Chief Technology Officer. “As a pioneer in precision medicine QIAGEN brings extensive experience in companion diagnostics, including ten FDA-approved tests.”

QIAGEN is the global leader in collaborations with pharmaceutical and biotechnology companies to co-develop companion diagnostics, which detect clinically relevant genetic abnormalities to provide insights that guide clinical decision-making in diseases such as cancer. The company has an unmatched depth and breadth of technologies from next-generation sequencing (NGS) to polymerase chain reaction (PCR) for companion diagnostic development. Its ten PCR-based CDx tests with FDA approval include therascreen EGFR for non-small cell lung cancer, therascreen KRAS for colorectal cancer, therascreen FGFR for urothelial cancer, therascreen PIK3CA for breast cancer based on tissue or plasma samples and the therascreen BRAF kit for colorectal cancer.

Currently, QIAGEN is working under master collaboration agreements with more than 25 companies to develop and commercialize companion diagnostic tests for their drug candidates – a deep pipeline of potential future products to advance Precision Medicine for the benefit of patients.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of September 30, 2021, QIAGEN employed approximately 6,000 people in over 35 locations worldwide.

About Denovo Biopharma

Denovo Biopharma LLC is a clinical-stage biopharmaceutical company that uses novel biomarker approaches to re-evaluate medicines that have failed in broad patient populations. The company seeks to discover genomic biomarkers correlated with patients’ responses to drug candidates retrospectively. Denovo then designs and executes efficient clinical trials in targeted patient populations to optimize the probability of a successful trial. Denovo has completed enrollment of patients in the US and China with DLBCL in a Phase 3 clinical trial and has an ongoing Phase 3 trial in GBM for its lead product candidate, DB102 (enzastaurin), which was in-licensed from Eli Lilly & Co. The company has seven additional late-stage programs targeting major unmet medical needs: DB103 (pomaglumetad methionil) for schizophrenia, DB104 (liafensine) for depression, DB105 (ORM 12741) for Alzheimer’s Disease, DB106 (vosaroxin) for acute myeloid leukemia (AML), DB107 (Toca 511/Toca FC) for recurrent high grade glioma, DB108 (endostatin) for non-small cell lung cancer (NSCLC), and DB109 (idalopirdine) for Alzheimer’s Disease.

LG and Lenovo team up to drive innovation in radiology and imaging

Lenovo and LG Electronics are working together to advance new medical imaging solutions for the radiology community. The offering bundles LG’s high-performance medical monitors with the Lenovo OEM Solutions commercial third-party portfolio of offerings.

On the heels of RSNA 2021, the annual meeting of the Radiological Society of North America, the Lenovo-LG bundle will provide diagnostic and clinical solutions in key imaging areas through the combination of Lenovo ThinkStation workstations and LG Medical Monitors.

The global pandemic has become a catalyst for digital transformation and accelerated the push to develop new solutions that operate efficiently in dynamic technology ecosystems. The radiology information systems market is expected to be worth over $979M by 2025, representing a CAGR of 7.4%.1

“Proven technologies that can support the most advanced AI-enhanced medical imaging solutions, including object detection and segmentation, are being increasingly adopted by healthcare systems. Lenovo workstations combined with LG medical monitors are rising to the opportunity to advance healthcare,” said Tom Hurlbut, Lenovo OEM Business General Manager & Global Executive.

“LG’s clinical and diagnostic medical monitors are designed to empower health care professionals to make informed life-saving decisions,” said Brian Fabrizio, medical information displays team leader at LG Business Solutions USA. “Working with Lenovo helps streamline the purchase process for LG medical monitors.”

‘Perfect Match’ for Medical Solution Developers

Complementing Lenovo’s ThinkStation workstations, LG’s healthcare monitors enable improved quality of medical services, providing consistent, high quality images.

“As we expand our third-party offerings, this LG medical monitor collaboration is a timely decision for powering what’s next in healthcare and radiology. The predictability and reliability of our ThinkStation portfolio matched with the quality and performance of LG monitors is the perfect match for medical solution developers,” said Hurlbut.

 

About Lenovo
Lenovo is a US$60 billion revenue Fortune Global 500 company serving customers in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that power (through devices and infrastructure) and empower (through solutions, services and software) millions of customers every day and together create a more inclusive, trustworthy and sustainable digital society for everyone, everywhere. To find out more visit?https://www.lenovo.com and read about the latest news via?our?StoryHub.

About LG Business Solutions USA
The LG Electronics USA Business Solutions division serves commercial display customers in the U.S. healthcare, lodging and hospitality, digital signage, systems integration, education, government and industrial markets. Based in Lincolnshire, Ill., with its dedicated engineering and customer support team, LG Business Solutions USA delivers business-to-business technology solutions tailored to the particular needs of business environments. LG Electronics USA Inc., based in Englewood Cliffs, N.J., is the North American subsidiary of LG Electronics Inc., a $56 billion global force in consumer electronics, home appliances and air solutions. LG is a seven-time ENERGY STAR® Partner of the Year.

Translate »